Table 1 A list of the medications chosen for clinical trials against B7-H3 [175]
Trial ID | Drugs | Cancer types | Trial stage | Start date | Completion date | Recruitment status |
|---|---|---|---|---|---|---|
Targeting B7-H3 with monoclonal antibodies | ||||||
 NCT01391143 | MGA271 | Refractory cancer, melanoma, prostate, solid tumors | Phase l | July 2011 | April 18, 2019 | Completed |
 NCT02982941 | MGA271 | Pediatric patients with relapsed or refractory solid tumors | Phase l | December 2016 | May 22, 2019 | Completed |
 NCT02923180 | MGA271 | Prostate Cancer | Phase II | February 14, 2017 | August 11, 2020 | Active, not recruiting |
 NCT02381314 | MGA271 | Melanoma Non Small Cell Lung Cancer | Phase l | March 26, 2015 | September 26, 2018 | Completed |
Targeting B7-H3 with bispecific antibodies | ||||||
 NCT03406949 | MGD009/MGA012 | Relapsed/Refractory Cancer | Phase I | February 27, 2018 | April 27, 2022 | Completed |
 NCT02628535 | MGD009 | Mesothelioma and 11 other cancers | Phase I | September 2015 | November 25, 2019 | Terminated |
Targeting B7-H3 through ADC therapies | ||||||
 NCT03729596 | MGC018 | advanced solid tumors | Phase I/II | November 21, 2018 | May 2023 | Active, not recruiting |
 NCT02475213 | MGA271 with pembrolizumab | Melanoma Head and Neck Cancer Non Small Cell Lung Cancer Urethelial Carcinoma | Phase I | July 2015 | August 18, 2021 | Completed |
 NCT04145622 | DS-7300a | Advanced Solid Tumor, Malignant Solid Tumor | Phase I/II | November 3, 2019 | December 1, 2023 | Recruiting |
 NCT05280470 | DS-7300a | Extensive-stage Small-cell Lung Cancer | Phase II | June 17, 2022 | November 14, 2024 | Recruiting |
Targeting B7-H3 with CAR T cells | ||||||
 NCT04185038 | SCRI-CARB7H3 | Ependymoma Germ Cell Tumor Diffuse Midline Glioma | Phase I | December 11, 2019 | May 2041 | Recruiting |
 NCT04077866 | B7-H3 CAR-T | Recurrent Glioblastoma, Refractory Glioblastoma | Phase I/II | June 1, 2023 | August 1, 2025 | Recruiting |
 NCT04385173 | B7-H3 CAR-T | Recurrent Glioblastoma, Refractory Glioblastoma | Phase I | December 1, 2022 | May 1, 2024 | Recruiting |
 NCT04483778 | 4-1BBζ B7H3-EGFRt-DHFR | Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma | Phase I | July 13, 2020 | December 2040 | Recruiting |
 NCT04432649 | 4SCAR-276 | Solid Tumor | Phase I/II | June 1, 2020 | May 31, 2024 | Recruiting |
 NCT05143151 | CD276 CAR-T cells | Advanced Pancreatic Carcinoma | Phase I/II | July 1, 2021 | July 2024 | Recruiting |
 NCT05190185 | TAA06 | Malignant Melanoma, Lung Cancer, or Colorectal Cancer | Phase I | June 1, 2021 | December 1, 2023 | Recruiting |
 NCT04692948 | TAA06 | CAR Acute Myeloid Leukemia | Not Applicable | December 9, 2019 | December 2023 | Recruiting |
 NCT04637503 | Combined 4SCAR-276 | Neuroblastoma | Phase I/II | November 18, 2020 | December 31, 2023 | Recruiting |
 NCT04432649 | 4SCAR-276 | Solid Tumor | Phase I/II | June 1, 2020 | May 31, 2024 | Recruiting |
Targeting B7-H3 with CAR NK cells | ||||||
 NCT03056339 | AP1903 | B-Lymphoid Malignancies | Phase I/II | June 21, 2017 | June 30, 2024 | Active, not recruiting |
 NCT04630769 | MGA271/ FT516 and IL2 | Ovarian cancer | Phase I | April 2, 2021 | January 1, 2022 | Recruiting |
Radioimmunotherapy | ||||||
 NCT01502917 | 124I-omburtamab | Brain cancer Brain Stem Glioma | Phase I | December 2011 | January 2022 | Completed |
 NCT01099644 | 131I-omburtamab | Peritoneal Cancer | Phase I | April 2010 | September 2022 | Active, not recruiting |
 NCT00089245 | 131I-omburtamab | Brain and Central Nervous System Tumors Neuroblastoma Sarcoma | Phase I | July 2004 | July 1, 2025 | Active, not recruiting |
 NCT03275402 | 131I-omburtamab | Neuroblastoma CNS Metastases Leptomeningeal Metastases | Phase II/III | December 11, 2018 | December 2026 | Recruiting |
 NCT05063357 | 131I-Omburtamab | DIPG | Phase I | March 2023 | January 31, 2027 | Not yet recruiting |
 NCT04022213 | 131I-Omburtamab | Desmoplastic Small Round Cell Tumor Peritoneal Cancer Peritoneal Carcinoma | Phase II | July 15, 2019 | July 2024 | Recruiting |
 NCT04743661 | 131I-omburtamab | Recurrent Medulloblastoma Recurrent Ependymoma | Phase II | April 4, 2022 | October 30, 2029 | Active, not recruiting |
 NCT04167618 | 177Lu-DTPA-omburtamab | Medulloblastoma, Childhood | Phase I/II | September 30, 2021 | August 11, 2022 | Terminated |